Short Communication - (2025) Volume 9, Issue 4
Received: 01-Aug-2025, Manuscript No. jid-26-187022;
Editor assigned: 04-Aug-2025, Pre QC No. P-187022;
Reviewed: 18-Aug-2025, QC No. Q-187022;
Revised: 22-Aug-2025, Manuscript No. R-187022;
Published:
29-Aug-2025
, DOI: 10.37421/2684-4559.2025.9.343
Citation: Muller, Sophia. "Adenovirus Pneumonia: Immune Response and Antiviral Strategies." Clin Infect Dis 13 (2025):343.
Copyright: © 2025 Muller S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Severe adenovirus pneumonia poses a significant threat, particularly to immunocompromised individuals, necessitating a comprehensive understanding of its pathogenesis and treatment strategies. [1]
This review consolidates current knowledge regarding this challenging infection, focusing on clinical outcomes and the complexities of antiviral therapies. Early research has aimed to elucidate the varied presentations and management approaches for adenovirus pneumonia across different patient populations, acknowledging the persistent difficulties in achieving universally effective treatments and managing associated toxicities.[2] This field of study has explored the critical role of the host immune response in the severity of adenovirus pneumonia, highlighting how disruptions in immune cell function, especially T-cells and neutrophils, can exacerbate lung damage. Identifying these immunopathological pathways is vital for developing therapies that can modulate the immune system in conjunction with direct antiviral interventions.[3] Furthermore, significant attention has been directed towards the specific hurdles encountered in treating adenovirus pneumonia in solid organ transplant recipients. Investigations in this area examine the broad spectrum of adenoviral disease observed in these vulnerable individuals, the therapeutic regimens that have been employed, and the demonstrable impact of combination antiviral treatments on both graft survival and overall patient mortality rates.[4] More specifically, the efficacy and safety profile of cidofovir, a key antiviral agent, for severe adenovirus infections has been a subject of rigorous study. This research provides crucial data derived from real-world clinical settings, detailing optimal dosing strategies, recommended treatment durations, and the potential for dose-limiting renal toxicity. These insights are instrumental in defining cidofovir's role as a foundational element in the antiviral management of adenovirus pneumonia.[5] Alongside cidofovir, the emerging potential of brincidofovir has garnered considerable interest, particularly for its application in both the prophylaxis and treatment of adenovirus infections. Studies emphasize its potentially improved safety characteristics when contrasted with cidofovir, suggesting its broadened utility in preventing and treating severe forms of adenovirus pneumonia.[6] The diagnostic landscape of adenovirus pneumonia is also a critical area of investigation, with a focus on the interpretation of viral load measurements. Research has examined viral kinetics in both peripheral blood and respiratory samples, underscoring the importance of serial monitoring and its correlation with treatment efficacy and ultimate patient outcomes. This data guides crucial therapeutic decisions in complex clinical scenarios.[7] In the context of pediatric hematological stem cell transplantation, management strategies for severe adenovirus pneumonia have been synthesized, offering a consolidated overview for clinicians. This includes detailed information on the epidemiology of the disease, its characteristic clinical manifestations, diagnostic methodologies, and the range of available treatment options, encompassing both antiviral agents and essential supportive care.[8] Beyond transplantation, the use of combination antiviral therapy for severe adenovirus pneumonia in immunocompromised adults has been examined through case series. These studies offer valuable real-world insights into the specific regimens utilized, the observed rates of patient response to treatment, and any adverse events encountered, thereby contributing to a better understanding of the effectiveness of these complex therapeutic approaches. Specialized challenges associated with treating adenovirus infections post-lung transplantation have also been explored. This research assesses the effectiveness of various antiviral drugs and combination treatment strategies within this distinct patient group, critically addressing issues related to graft tolerance and the toxicities inherent in antiviral therapies.[9] Finally, the exploration of novel antiviral compounds and adjunctive therapeutic modalities for severe adenovirus pneumonia represents the frontier of research. This area delves into preclinical findings and early clinical data, offering a forward-looking perspective on potential future treatment avenues and the prospect of significantly improved clinical outcomes for affected patient. [10]The current understanding of severe adenovirus pneumonia in immunocompromised patients is being advanced through rigorous research, with a particular focus on the clinical outcomes associated with antiviral combination therapy. While specific agents such as cidofovir and brincidofovir show promise, the inherent challenges of achieving universally effective treatments, coupled with the potential for significant toxicity, remain central concerns. Efforts are increasingly directed towards refining patient population stratification, optimizing viral load monitoring, and developing innovative treatment strategies.[1]
Central to the pathogenesis of severe adenovirus pneumonia is the host immune response, which has been extensively investigated. Dysregulation within crucial immune cells, notably T-cells and neutrophils, has been identified as a significant contributor to the severity of lung damage. A deeper comprehension of these immunopathological mechanisms is considered paramount for the development of targeted therapies that can effectively modulate the host's inflammatory and immune responses in parallel with direct antiviral treatments.[2] The specific complexities of managing adenovirus pneumonia in the context of solid organ transplantation are a distinct area of focus. Research in this domain scrutinizes the full spectrum of adenoviral disease manifestations within this patient cohort, analyzes the therapeutic strategies that have been implemented, and evaluates the impact of various combination antiviral regimens on critical outcomes such as graft survival and patient mortality.[3] The therapeutic utility of cidofovir for severe adenovirus infections has been subjected to detailed examination, particularly concerning its efficacy and safety in real-world clinical scenarios. This research provides essential data on appropriate dosing protocols, optimal treatment durations, and the critical consideration of potential renal toxicity, thereby solidifying its position as a cornerstone antiviral therapy for adenovirus pneumonia.[4] Complementing cidofovir, brincidofovir is emerging as a promising agent for the management of adenovirus infections, with potential applications in both prophylaxis and treatment. Its distinct safety profile, often noted as being more favorable than that of cidofovir, suggests a broader applicability in the prevention and treatment of severe adenovirus pneumonia across various immunocompromised populations.[5] Accurate diagnosis and monitoring are indispensable, and research has underscored the importance of interpreting viral load dynamics in peripheral blood and respiratory samples. The correlation between serial viral load measurements, treatment response, and patient outcomes is crucial for guiding clinical decision-making in the management of adenovirus pneumonia, especially in complicated cases.[6] In pediatric hematopoietic stem cell transplant recipients, a comprehensive overview of the current management of severe adenovirus pneumonia has been established. This includes detailed insights into the disease's epidemiology, its diverse clinical presentations, effective diagnostic techniques, and the spectrum of treatment options, encompassing both antiviral medications and supportive care measures.[7] For immunocompromised adults suffering from severe adenovirus pneumonia, the effectiveness of combination antiviral therapy has been illuminated through case series. These studies offer pragmatic evidence regarding the specific therapeutic combinations used, the rates of clinical response observed, and any adverse events that arose, thereby enriching the collective understanding of real-world treatment efficacy.[8] Post-lung transplantation, the challenges associated with adenovirus infections require specialized therapeutic considerations. Studies in this area assess the effectiveness of different antiviral agents and combination therapies tailored to this specific patient group, paying close attention to the interplay between treatment efficacy, graft tolerance, and the development of treatment-related toxicities.[9] Looking toward the future, emerging antiviral therapies for severe adenovirus pneumonia are being actively investigated. This research explores novel antiviral compounds and adjunctive treatment modalities, presenting preclinical data and early clinical findings that offer a glimpse into future therapeutic directions and the potential for significant improvements in patient outcomes. [10]Severe adenovirus pneumonia is a significant concern for immunocompromised patients, with antiviral combination therapy showing promise but facing challenges due to toxicity and lack of universal efficacy. Research highlights the critical role of host immune response, particularly T-cells and neutrophils, in disease severity. Treatment strategies are tailored for specific populations like transplant recipients, with cidofovir and brincidofovir being key antiviral agents. Effective management relies on accurate viral load monitoring and understanding disease spectrum. Emerging therapies and novel compounds offer future hope for improved clinical outcomes.
Clinical Infectious Diseases: Open Access received 1149 citations as per Google Scholar report
